New cocktail of cancer drugs shows promise for tough lymphoma
Disease control
Recruiting now
This early-stage study is testing a drug called loncastuximab tesirine (ZYNLONTA) combined with other anti-cancer agents in people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. The main goal is to find safe doses and see how well the combinat…
Phase: PHASE1 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC